Establishment Labs (NASDAQ:ESTA) Given New $88.00 Price Target at BTIG Research

Establishment Labs (NASDAQ:ESTA) had its target price upped by BTIG Research from $86.00 to $88.00 in a report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also recently weighed in on ESTA. Citigroup increased their price target on Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Canaccord Genuity Group increased their target price on Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Needham & Company LLC boosted their price target on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday. Mizuho raised their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Establishment Labs presently has a consensus rating of “Moderate Buy” and an average price target of $79.43.

Establishment Labs Price Performance

NASDAQ ESTA opened at $79.67 on Tuesday. Establishment Labs has a one year low of $26.56 and a one year high of $79.90. The stock has a 50-day moving average of $70.99 and a 200 day moving average of $57.73. The company has a debt-to-equity ratio of 15.06, a quick ratio of 2.10 and a current ratio of 3.33. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -28.05 and a beta of 0.99.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The firm had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the previous year, the business posted ($1.19) earnings per share. On average, sell-side analysts forecast that Establishment Labs will post -2.41 EPS for the current year.

Institutional Trading of Establishment Labs

Institutional investors and hedge funds have recently modified their holdings of the company. Kestra Advisory Services LLC bought a new position in Establishment Labs in the 4th quarter worth $47,000. Quarry LP bought a new stake in Establishment Labs during the third quarter valued at about $34,000. State of Wyoming purchased a new position in shares of Establishment Labs in the third quarter valued at about $71,000. MV Capital Management Inc. bought a new position in shares of Establishment Labs in the fourth quarter worth about $146,000. Finally, Osaic Holdings Inc. boosted its stake in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after acquiring an additional 1,800 shares during the period. 72.91% of the stock is currently owned by institutional investors.

Key Stories Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q4 beat on both EPS and revenue: EST A reported ($0.09) EPS vs. consensus ($0.22) and revenue of $64.62M (up 45% YoY), signaling accelerating sales recovery and margin improvement potential. Read More.
• Positive Sentiment: 2026 revenue guidance and growth target: management guided FY-2026 revenue of $264–266M and is targeting at least 25% revenue growth while expanding minimally invasive platforms — a clear revenue-growth thesis for investors. Read More.
• Positive Sentiment: Analyst optimism: Needham raised its price target to $86 and kept a Buy rating, providing third-party validation and incremental buy-side support. Read More.
• Neutral Sentiment: Leadership transition announced to support next growth phase — could be constructive but depends on execution and message from new leadership. Read More.
• Neutral Sentiment: Full Q4/2025 disclosure and call details are available (earnings call transcript published), useful for assessing management commentary on margin levers and commercialization cadence. Read More.
• Neutral Sentiment: Industry/peer coverage and previews note narrowing losses and improving trends but don’t change the profitability timeline. Read More.
• Negative Sentiment: Company remains unprofitable with a negative net margin (~-43%) and negative ROE; sell-side still models negative EPS for the year — execution risks and profitability timeline could cap upside. Read More.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.